Bluejay Diagnostics (BJDX) Gross Margin (2022)
Bluejay Diagnostics (BJDX) posted Gross Margin of 19.64% for Q2 2022.
Bluejay Diagnostics (BJDX) Gross Margin (2022) Analysis & Trends
Bluejay Diagnostics has reported Gross Margin for 1 years, with the latest figure at 19.64% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 57.71% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 68.27% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 70.71% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 77.46% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 63.44% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 41.17% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 47.38% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 45.84% |
| 10 | Bluejay Diagnostics | 1.91 Mn | 1.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 19.64% |